{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luciano MT"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","Medical Research and Materiel Command","National Institute on Alcohol Abuse and Alcoholism","NIAAA NIH HHS"],"pagination":["157-166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9974893"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(1)"],"pubmed_abstract":["Trauma-informed beliefs often decrease during posttraumatic stress disorder (PTSD) treatment. This may also extend to anxiety sensitivity (AS), defined as a fear of anxiety-related sensations and beliefs that anxiety is dangerous and/or intolerable. However, little is known about how AS changes during exposure-based and psychopharmacological PTSD treatments. Further, high AS may be a risk factor for diminished PTSD symptom improvement and increased treatment dropout. To better understand how AS impacts and is impacted by PTSD treatment, we conducted a secondary analysis of a randomized clinical trial with a sample of 223 veterans (87.0% male, 57.5% White) with PTSD from four U.S. sites. Veterans were randomized to receive prolonged exposure (PE) plus placebo (n = 74), sertraline plus enhan"],"journal":["Journal of traumatic stress"],"pubmed_title":["The influence of posttraumatic stress disorder treatment on anxiety sensitivity: Impact of prolonged exposure, sertraline, and their combination."],"pmcid":["PMC9974893"],"funding_grant_id":["AA013525","UL1 TR002240","W81XWH‐11‐1‐0073","T32 AA013525","UL1TR000433","UL1 TR000433"],"pubmed_authors":["Acierno R","Martis B","Stein MB","Rauch SAM","Szuhany KL","Tuerk PW","Allard CB","Simon NM","PROGrESS Study Team","Baker AW","Luciano MT","Norman SB"],"additional_accession":[]},"is_claimable":false,"name":"The influence of posttraumatic stress disorder treatment on anxiety sensitivity: Impact of prolonged exposure, sertraline, and their combination.","description":"Trauma-informed beliefs often decrease during posttraumatic stress disorder (PTSD) treatment. This may also extend to anxiety sensitivity (AS), defined as a fear of anxiety-related sensations and beliefs that anxiety is dangerous and/or intolerable. However, little is known about how AS changes during exposure-based and psychopharmacological PTSD treatments. Further, high AS may be a risk factor for diminished PTSD symptom improvement and increased treatment dropout. To better understand how AS impacts and is impacted by PTSD treatment, we conducted a secondary analysis of a randomized clinical trial with a sample of 223 veterans (87.0% male, 57.5% White) with PTSD from four U.S. sites. Veterans were randomized to receive prolonged exposure (PE) plus placebo (n = 74), sertraline plus enhan","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T11:48:38Z","creation":"2025-02-19T04:59:45.419Z"},"accession":"S-EPMC9974893","cross_references":{"pubmed":["36451271"],"doi":["10.1002/jts.22894"]}}